TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8863084

Group type: EXPERIMENTAL
Intervention: Adolescents with invisible conditions
Number of subjects: 36284

Group type: EXPERIMENTAL
Intervention: Adolescents with visible conditions
Number of subjects: 36284

Group type: EXPERIMENTAL
Intervention: Adolescents with chronic conditions
Number of subjects: 36284

Group type: COMPARATOR
Intervention: Adolescents without chronic conditions (controls)
Number of subjects: 36284
Study: 1737074

Group type: EXPERIMENTAL
Intervention: Bright white light treatment (2000‐3000 lux)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dim red light placebo control treatment
Number of subjects: 51
Study: 6093524

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g once daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cefazolin 1 g three times daily
Number of subjects: 110
Study: 30666071

Group type: EXPERIMENTAL
Intervention: Intralesional MMR vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 60
Study: 29218667

Group type: EXPERIMENTAL
Intervention: Transvaginal cholecystectomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 90
Study: 27027655

Group type: EXPERIMENTAL
Intervention: 5-mg once-yearly infusions of zoledronic acid
Number of subjects: 7765

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7765
Study: 23990605

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 1112
Study: 22849427

Group type: EXPERIMENTAL
Intervention: Quetiapine (QUET)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 26
Study: 19665818

Group type: EXPERIMENTAL
Intervention: Infliximab/docetaxel
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo/docetaxel
Number of subjects: 61
Study: 18503512

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (Sleep at Home)
Number of subjects: 28
Study: 15765222

Group type: EXPERIMENTAL
Intervention: Presence of IA-2A autoantibodies
Number of subjects: 2556

Group type: EXPERIMENTAL
Intervention: Presence of IA-2A and GADA autoantibodies
Number of subjects: 2556

Group type: EXPERIMENTAL
Intervention: Presence of IA-2betaA autoantibodies
Number of subjects: 2556
Study: 12443576

Group type: EXPERIMENTAL
Intervention: Routine therapy plus anisodamine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine therapy only
Number of subjects: 90
Study: 10546304

Group type: EXPERIMENTAL
Intervention: Swimming without water protection (Group I)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Swimming with water protection (Group II)
Number of subjects: 86
Study: 8652322

Group type: EXPERIMENTAL
Intervention: Bair Hugger blanket on high setting
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (aluminized plastic 'space' blanket)
Number of subjects: 20
Study: 1855280

Group type: EXPERIMENTAL
Intervention: batanopride
Number of subjects: 21

Group type: COMPARATOR
Intervention: metoclopramide
Number of subjects: 21
Study: 6749701

Group type: EXPERIMENTAL
Intervention: Isoaminile citrate (40 mg, 3 x daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chlophedianol hydrochloride (20 mg, 3 x daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chlophedianol hydrochloride (20 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isoaminile citrate (40 mg)
Number of subjects: 66
Study: 30092772

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care by mother (kangaroo care) plus tactile-kinesthetic stimulation by mothers from randomization until hospital discharge, followed by a program of early intervention with 10 parents' orientation and 10 home visits.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care according to the routine care of the NICU.
Number of subjects: 0
Study: 27724972

Group type: EXPERIMENTAL
Intervention: Scalp Acupuncture (SA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scalp Acupuncture and Electromagnetic Convergence Stimulation (SAEM-CS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Stroke Rehabilitation (Control)
Number of subjects: 60
Study: 25716730

Group type: EXPERIMENTAL
Intervention: MMSC infusion after allo-BMT
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard prophylaxis of aGVHD
Number of subjects: 77
Study: 24429864

Group type: EXPERIMENTAL
Intervention: Kombinil-Duo ear drops
Number of subjects: 55

Group type: COMPARATOR
Intervention: Traditional methods
Number of subjects: 55
Study: 19823880

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional ultrasonic debridement (UST)
Number of subjects: 54
Study: 17973163

Group type: EXPERIMENTAL
Intervention: TOGa system (transoral gastroplasty)
Number of subjects: 21
Study: 16054579

Group type: EXPERIMENTAL
Intervention: Dynamic block-randomization algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 14559411

Group type: EXPERIMENTAL
Intervention: Ecological task instruction
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: On-product information (OPI)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Kettle design
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: User variables (habits, environmental concern, control beliefs)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: User variable (knowledge)
Number of subjects: 48
Study: 10539815

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6758

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6758

Group type: EXPERIMENTAL
Intervention: Both groups (enalapril and placebo)
Number of subjects: 6758
Study: 9345432

Group type: EXPERIMENTAL
Intervention: Clinical examination of spasticity
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Achilles tendon reflex score
Number of subjects: 35
Study: 1866755

Group type: EXPERIMENTAL
Intervention: Oral dextromethorphan (60 mg q.i.d.) for 3 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6629289

Group type: EXPERIMENTAL
Intervention: Hypocaloric weight reduction diets
Number of subjects: 40
Study: 30456899

Group type: EXPERIMENTAL
Intervention: IqYmune®
Number of subjects: 22

Group type: COMPARATOR
Intervention: Kiovig®
Number of subjects: 22
Study: 29497826

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 70
Study: 25875959

Group type: EXPERIMENTAL
Intervention: Novel commissioning of NHS stop smoking services with payment for quits achieved.
Number of subjects: 2138947

Group type: COMPARATOR
Intervention: Control group of PCTs without novel commissioning arrangements.
Number of subjects: 2138947

Group type: EXPERIMENTAL
Intervention: Largest two providers in intervention PCTs.
Number of subjects: 2138947

Group type: EXPERIMENTAL
Intervention: New market entrants in intervention PCTs.
Number of subjects: 2138947
Study: 23525797

Group type: EXPERIMENTAL
Intervention: TP53 mutations
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: del17p
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Complete disruption of TP53 function (combination of point mutations and/or del17p)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Heterozygous TP53 mutation
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Complete loss of TP53 function
Number of subjects: 457
Study: 21737827

Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 8
Study: 19698011

Group type: EXPERIMENTAL
Intervention: Combination therapy with losartan 50 mg and hydrochlorothiazide 12.5 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Losartan 100 mg/day (control group)
Number of subjects: 60
Study: 17294322

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 84
Study: 14973803

Group type: EXPERIMENTAL
Intervention: Acupressure treatment (n = 75)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo (n = 77)
Number of subjects: 152
Study: 11443510

Group type: EXPERIMENTAL
Intervention: Light work-related physical activity
Number of subjects: 2488

Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 2488

Group type: COMPARATOR
Intervention: Baseline energy intake, physical activity at work, alcohol consumption, smoking status
Number of subjects: 2488

Group type: COMPARATOR
Intervention: Control variables (baseline weight, weight status, height, age, residence, income, educational attainment)
Number of subjects: 2488
Study: 9619146

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 75
Study: 7605702

Group type: EXPERIMENTAL
Intervention: Osteocalcin (Oc) levels in women with hip fracture
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase (ALP) levels in women with hip fracture
Number of subjects: 58
Study: 2123042

Group type: EXPERIMENTAL
Intervention: Health education intervention by phone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education intervention by home visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education intervention by doctor in office
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 324488

Group type: EXPERIMENTAL
Intervention: Oxprenolol (1-(o-allyloxy-phenoxy)-3-isopropylamino-propan-2-ol hydrochloride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31991236

Group type: EXPERIMENTAL
Intervention: Long-term exposure to nitrogen dioxide (NO2)
Number of subjects: 5485

Group type: EXPERIMENTAL
Intervention: Long-term exposure to ozone (O3)
Number of subjects: 5485

Group type: EXPERIMENTAL
Intervention: Long-term exposure to fine particulate matter (PM2.5)
Number of subjects: 5485

Group type: EXPERIMENTAL
Intervention: Bayesian Kernel machine regression (BKMR)
Number of subjects: 5485

Group type: EXPERIMENTAL
Intervention: Logistic regression models
Number of subjects: 5485
Study: 31178422

Group type: EXPERIMENTAL
Intervention: macitentan 10 mg once daily
Number of subjects: 85

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study: 25415393

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation application and conventional physiotherapy (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional physiotherapy alone (group B)
Number of subjects: 28
Study: 22336903

Group type: EXPERIMENTAL
Intervention: 640 mg anthocyanins daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 22132138

Group type: EXPERIMENTAL
Intervention: BIS-guided propofol infusion titrated to a BIS level of 65-75
Number of subjects: 500

Group type: COMPARATOR
Intervention: Incremental midazolam bolus based on clinical judgment
Number of subjects: 500
Study: 18654005

Group type: EXPERIMENTAL
Intervention: Phase III cardiac rehabilitation program (exercise training, diet therapy, and weekly counseling for 6 months)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual outpatient care
Number of subjects: 34
Study: 17054108

Group type: EXPERIMENTAL
Intervention: FEC-HD (fluorouracil 750 mg/m(2) on Days 1 to 4, epirubicin 35 mg/m(2) on Days 2 to 4, cyclophosphamide 400 mg/m(2) on Days 2 to 4 for 4 cycles every 21 days) with lenograstim
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FEC 75 (fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), cyclophosphamide 500 mg/m(2) on Day 1 every 21 days for 4 cycles)
Number of subjects: 120

Group type: COMPARATOR
Intervention: FEC-HD (without lenograstim)
Number of subjects: 120
Study: 14609434

Group type: EXPERIMENTAL
Intervention: Bravelle
Number of subjects: 238

Group type: COMPARATOR
Intervention: Follistim
Number of subjects: 238
Study: 10998604

Group type: EXPERIMENTAL
Intervention: LOW threat condition (40 cm)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: MEDIUM threat condition (100 cm)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: HIGH threat condition (160 cm)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Descending order (HIGH threat first)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ascending order (LOW threat first)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: First trial at LOW threat condition
Number of subjects: 62
Study: 8694298

Group type: EXPERIMENTAL
Intervention: Propofol 1.25 or 2.5 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eltanolone 0.5 or 1 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lipid emulsion only
Number of subjects: 0
Study: 1461627

Group type: EXPERIMENTAL
Intervention: Low-dose megestrol acetate (480 mg/day)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (960 mg/day)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 6322207

Group type: EXPERIMENTAL
Intervention: Enalapril maleate (10 to 40 mg per day) with hydrochlorothiazide (50 mg per day) and alpha-methyldopa (250 to 1000 mg per day if necessary)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg per day) with propranolol (80 to 240 mg per day) and hydralazine (100 to 200 mg per day if necessary)
Number of subjects: 24
Study: 30855708

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (10 sessions, one daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo rTMS treatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 82
Study: 29463150

Group type: EXPERIMENTAL
Intervention: 3.75 mg prasugrel
Number of subjects: 3747

Group type: COMPARATOR
Intervention: 75 mg clopidogrel
Number of subjects: 3747
Study: 26903430

Group type: EXPERIMENTAL
Intervention: Rap music use
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Perceived peer sexual behavior (mediator)
Number of subjects: 443
Study: 24583820

Group type: EXPERIMENTAL
Intervention: 8 mg i.v. dexamethasone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22788925

Group type: EXPERIMENTAL
Intervention: Immune-enhanced enteral nutrition (EN + glutamine [Gln])
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Standard enteral nutrition (EN)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 20961269

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Calcium supplementation (1000 mg/day)
Number of subjects: 132
Study: 17714677

Group type: EXPERIMENTAL
Intervention: Unprotected intercourse (no barrier contraception)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male partner's unwillingness to use condoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low condom use self‐efficacy score (for women < 20 years old)
Number of subjects: 0
Study: 15653007

Group type: EXPERIMENTAL
Intervention: Low-dose continuous combined HRT (1 mg 17beta-estradiol plus 0.5 mg norethisterone acetate)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sequential combined HRT (0.625 mg conjugated equine estrogens for 28 days plus 5 mg medrogestone for 14 days)
Number of subjects: 100
Study: 12040969

Group type: EXPERIMENTAL
Intervention: Diclofenac effervescent tablet (DIC-BT) 150 mg/d for 7 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diclofenac enteric coated dragees (DIC-mrD) 150 mg/d for 7 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible tablets (DIC-DispT) 150 mg/d for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 1500 mg/d for 7 days (positive control)
Number of subjects: 100
Study: 9620500

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (CE) 100 mg i.v. (20 mL) at the beginning of the procedure and a second dose of CE (100 mg i.v.) just after reperfusion of the new graft.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (20 mL of isotonic sodium chloride solution) at the beginning of the procedure and a second dose of placebo (20 mL of isotonic sodium chloride solution) just after reperfusion of the new graft.
Number of subjects: 0
Study: 10150762

Group type: EXPERIMENTAL
Intervention: Veno-venous bypass
Number of subjects: 8
Study: 2360542

Group type: EXPERIMENTAL
Intervention: New milk product (860 mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal milk (1000 mL)
Number of subjects: 0
Study: 466138

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 53
Study: 30829563

Group type: COMPARATOR
Intervention: Family history of stroke (overall)
Number of subjects: 3878

Group type: COMPARATOR
Intervention: Maternal stroke history
Number of subjects: 3878

Group type: COMPARATOR
Intervention: Stroke onset age <55 years with family history
Number of subjects: 3878

Group type: COMPARATOR
Intervention: Thrombotic stroke in patients with family history
Number of subjects: 3878
Study: 27919204

Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SPT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 87
Study: 25850535

Group type: EXPERIMENTAL
Intervention: Multi-frequency bioimpedance electrical analysis (BIS)
Number of subjects: 964

Group type: COMPARATOR
Intervention: Perometer arm measurement
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Both methods (BIS and Perometer)
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Threshold for early intervention
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Symptoms reported by patients with no lymphoedema
Number of subjects: 964
Study: 23426275

Group type: EXPERIMENTAL
Intervention: Advanced Care Group (ACG) - received usual care plus regular information and encouragement on cardiovascular risk factors by email or letter.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - received regular care.
Number of subjects: 55
Study: 20605698

Group type: EXPERIMENTAL
Intervention: Vitamin A plus iron, thiamine, riboflavin, folic acid, niacinamide, zinc, and calcium (Group III)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Vitamin A plus iron (Group II)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Vitamin A (Group I)
Number of subjects: 226
Study: 19438468

Group type: EXPERIMENTAL
Intervention: Supratrochlear and supraorbital nerve block
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cold air analgesia
Number of subjects: 34
Study: 17265458

Group type: EXPERIMENTAL
Intervention: T2000 (400 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: T2000 (300 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Comparison of T2000 (800 mg daily)
Number of subjects: 34
Study: 15141410

Group type: EXPERIMENTAL
Intervention: Soluble fiber diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insoluble fiber diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intragastric feeding
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no fiber added)
Number of subjects: 8
Study: 12666946

Group type: EXPERIMENTAL
Intervention: 25% metronidazole dental gel applied subgingivally on days 0 and 7 as an adjunct to scaling and root planing (SRP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 18
Study: 9210122

Group type: EXPERIMENTAL
Intervention: Linear amplification
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: BILL processing
Number of subjects: 110
Study: 7659916

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine solution using 50% dimethylsulfoxide as a vehicle
Number of subjects: 8

Group type: COMPARATOR
Intervention: Similar solution without cyclosporine
Number of subjects: 8
Study: 2891032

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 130

Group type: COMPARATOR
Intervention: Antacids or H2 blockers
Number of subjects: 130
Study: 29510649

Group type: EXPERIMENTAL
Intervention: Letrozole (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 27824633

Group type: EXPERIMENTAL
Intervention: Inositol (6 to 18 g/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 25749502

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/d for 5 days and then every third day (12 total doses) + darbopoietin α 40 mcg/wk for 4 weeks (GDP group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) + darbopoietin α (GDP group)
Number of subjects: 55
Study: 23438706

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 115

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 115
Study: 20403998

Group type: EXPERIMENTAL
Intervention: Statin use (36% of participants, n = 730)
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: Statin use for >3 years
Number of subjects: 2035

Group type: COMPARATOR
Intervention: Celecoxib treatment (200 mg and 400 mg)
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 2035
Study: 18280869

Group type: EXPERIMENTAL
Intervention: Lidcombe Program for 16 weeks
Number of subjects: 46
Study: 15718182

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (outpatient heart failure clinic)
Number of subjects: 200
Study: 12456380

Group type: EXPERIMENTAL
Intervention: Intravenous montelukast (7 or 14 mg)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 10615075

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion of floxuridine plus systemic fluorouracil (with or without leucovorin)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Systemic therapy alone (monotherapy)
Number of subjects: 156
Study: 8941833

Group type: EXPERIMENTAL
Intervention: Tetracycline fibers
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tetracycline fibers with scaling and root planing
Number of subjects: 25
Study: 1768058

Group type: EXPERIMENTAL
Intervention: Abrasio only treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: High dose gestagen therapy recommended for patients with CGH and high PgR concentration
Number of subjects: 63
Study: 7009309

Group type: EXPERIMENTAL
Intervention: End-to-side portacaval shunt
Number of subjects: 89

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 89